{"id":311,"date":"2022-01-25T00:01:03","date_gmt":"2022-01-25T00:01:03","guid":{"rendered":"https:\/\/mexusnews.com\/espanol\/?p=311"},"modified":"2022-02-04T23:00:07","modified_gmt":"2022-02-04T23:00:07","slug":"es-el-doctor-robert-malone-el-inventor-de-las-vacunas-arnm-aqui-estan-las-patentes","status":"publish","type":"post","link":"https:\/\/mexusnews.com\/espanol\/2022\/01\/es-el-doctor-robert-malone-el-inventor-de-las-vacunas-arnm-aqui-estan-las-patentes\/","title":{"rendered":"Es el doctor Robert Malone el inventor de las vacunas Covid-19 de ARNm?  Aqu\u00ed est\u00e1n las patentes"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-358\" src=\"https:\/\/mexusnews.com\/espanol\/wp-content\/uploads\/2022\/01\/IMG_20220204_175856_608.jpg\" alt=\"\" width=\"1199\" height=\"678\" srcset=\"https:\/\/mexusnews.com\/espanol\/wp-content\/uploads\/2022\/01\/IMG_20220204_175856_608.jpg 1199w, https:\/\/mexusnews.com\/espanol\/wp-content\/uploads\/2022\/01\/IMG_20220204_175856_608-300x170.jpg 300w, https:\/\/mexusnews.com\/espanol\/wp-content\/uploads\/2022\/01\/IMG_20220204_175856_608-1024x579.jpg 1024w, https:\/\/mexusnews.com\/espanol\/wp-content\/uploads\/2022\/01\/IMG_20220204_175856_608-768x434.jpg 768w, https:\/\/mexusnews.com\/espanol\/wp-content\/uploads\/2022\/01\/IMG_20220204_175856_608-640x362.jpg 640w\" sizes=\"auto, (max-width: 1199px) 100vw, 1199px\" \/>Patentes del Dr. Malone de el.inventobdeblas vacunas que se usan en las vacunas<\/p>\r\n<p>Pfizer yvMODERN Early Patents priority dates from 1989<br \/>The first patents:<\/p>\r\n<!-- \/wp:post-content -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US6867195B1\/en\">Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response (includes mRNA)<\/a>. P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. No. 7,250,404, date of issue: 7\/31\/07 Cited in 105 articles. Priority Date: 3\/21\/1989.<\/li>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US20030032615A1\/en\">https:\/\/patents.google.com\/patent\/US20030032615A1\/en<\/a><\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US6867195B1\/en\">Lipid-mediated polynucleotide administration to reduce likelihood of subject&#8217;s becoming infected<\/a> (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,867,195 B1. Date of issue: 3\/15\/05. Priority Date: 3\/21\/1989.<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US6867195B1\/en\">Generation of an immune response to a pathogen (includes mRNA). <\/a>P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,710,035. Date of issue: 3\/23\/04. Citations: 39 articles. Priority Date: 3\/21\/1989.<\/li>\r\n<li>https:\/\/patents.google.com\/patent\/US6867195B1\/en<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US6673776B1\/en\">Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human (includes mRNA).<\/a> P Felgner, JA Wolff, GH Rhodes, <strong>Robert W Malone<\/strong>, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,673,776. Date of issue: 1\/6\/04. Priority Date: 3\/21\/1989.<\/li>\r\n<li>https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/6710035-B2US-<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/app.dimensions.ai\/details\/patent\/US-6413942-B1\">Methods of delivering a physiologically active polypeptide to a mammal (includes mRNA).<\/a> P Felgner, JA Wolff, GH Rhodes, <strong>Robert W Malone<\/strong>, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,413,942. Date of issue: 7\/2\/02. (cited in 150 articles). Priority Date: 3\/21\/1989.<\/li>\r\n<li>https:\/\/app.dimensions.ai\/details\/patent\/US-6413942-B1<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US6214804B1\/en\">Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA).<\/a> P Felgner, JA Wolff, GH Rhodes, <strong>Robert W Malone<\/strong>, D Carson. Assigned to Vical, licensed to Merck. US Pat. Ser. No. 6,214,804, date of issue: 4\/10\/01. Cited in 360 articles. Priority Date: 3\/21\/1989.<\/li>\r\n<li>https:\/\/patents.google.com\/patent\/US6214804B1\/en<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US5589466A\/en\">Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA). <\/a>P Felgner, JA Wolff, GH Rhodes, <strong>Robert W Malone<\/strong>, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,589,466. Date of issue: 12\/31\/96. Cited in 899 articles. Priority Date: 3\/21\/1989.<\/li>\r\n<li>https:\/\/patents.google.com\/patent\/US5589466A\/en<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>============================<\/p>\r\n<p><iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" title=\"Dr. Robert Malone, Mr Steve Kirsch &amp; Dr. Bret Weinstein - How to save the world in three easy steps.\" width=\"459\" height=\"344\" src=\"https:\/\/www.bitchute.com\/embed\/1OIllAyUMXml\/?feature=oembed#?secret=Ha1cZeRhOe\" data-secret=\"Ha1cZeRhOe\" frameborder=\"0\"><\/iframe><\/p>\r\n<p>INTERVIEW WITJ <strong>DR<\/strong>. <strong>ROBERT MALONE<\/strong>, MD &amp; SCIENTIST,\u00a0 MR <strong>STEVE KIRSCH, <\/strong>ENGINEER INVENTOR, AND<strong> DR. BRET WEINSTEIN<\/strong>, PHD IN BIOLOGY SPECIALIZED IN EVOLUTION AND IMMUNO-BIOLOGY.\u00a0<\/p>\r\n<p>Below are some of the descriptions of the invention taken from the above patents &#8211; priority date 1989.<\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US5703055A\/en\">Generation of antibodies through lipid mediated DNA delivery (includes mRNA<\/a>). P Felgner, JA Wolff, GH Rhodes, <strong>Robert W Malone<\/strong>, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,703,055. Date of issue: 12\/30\/97. Cited in 419 articles. Priority Date: 3\/21\/1989.<\/li>\r\n<li>https:\/\/patents.google.com\/patent\/US5703055A\/en<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>Source: https:\/\/t.me\/RWMaloneMD\/1230<\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p><strong>Some of Doctor Robert Malon papers and other patents on this subject area (1988-2000).<\/strong><\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/www.rwmalonemd.com\/s\/J-A-Novel-Approach-to-Study-Packagnng-Ret-RNA-by-RNA-Tran-Malone-ColdSpringHarborpdf.pdf\">A novel approach to study packaging of retroviral RNA by RNA transfection (Abstract).<\/a> <strong>RW Malone<\/strong>, P. Felgner, I. Verma. RNA Tumor Viruses, May 17-18, 1988. Cold Spring Harbor (the first in a series of papers\/abstracts on RNA transfection). https:\/\/www.rwmalonemd.com\/s\/J-A-Novel-Approach-to-Study-Packagnng-Ret-RNA-by-RNA-Tran-Malone-ColdSpringHarborpdf.pdf<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/www.rwmalonemd.com\/s\/KFocusmRNATransfectofCulturedEukCellembryos1989Data198820210212.pdf\"><strong>mRNA Transfection of cultured eukaryotic cells and embryos using cationic liposomes<\/strong><\/a>. <strong>Malone RW<\/strong>. Focus. 1989; 11:61-8<\/li>\r\n<li>https:\/\/www.rwmalonemd.com\/s\/KFocusmRNATransfectofCulturedEukCellembryos1989Data198820210212.pdf<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/www.rwmalonemd.com\/s\/B-Cationic-Lipid-Mediated-RNA-and-DNA-patent-1988-Salk-Malon.pdf\">The SALK patent that was filed with the USPTO on 3\/21\/1989<\/a>. Note that the cover letter hides this &#8211; and says it was filed on 3\/29\/89 &#8211; the sane date as all the VICAL patents, showing that there was collusion. WRITTEN BY DR. MALONE IN 1988.<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/www.rwmalonemd.com\/s\/First-mRNA-vaccination-data-March-21-1990.pdf\"><strong>THE VERY FIRST mRNA VACCINE EXPERIMENTAL DATA 1990 (from Vical to patent office)<\/strong><\/a> https:\/\/www.rwmalonemd.com\/s\/First-mRNA-vaccination-data-March-21-1990.pdf<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/www.rwmalonemd.com\/s\/First-mRNA-vaccination-data-March-21-1990.pdf\">Cationic liposome-mediated RNA transfection. Malone RW, Felgner PL, Verma IM. Proc Natl Acad Sci (PNAS) U S A. 1989;86(16):6077-81. Cited in 749 articles.<\/a><\/li>\r\n<li><a href=\"https:\/\/science.sciencemag.org\/content\/247\/4949\/1465\">https:\/\/www.rwmalonemd.com\/s\/vaccination-data-March-21-1990.pdfFirst-mRNA<\/a><a href=\"https:\/\/science.sciencemag.org\/content\/247\/4949\/1465\">&#8211;<\/a><\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/science.sciencemag.org\/content\/247\/4949\/1465\">Direct gene transfer into mouse muscle in vivo. Wolff JA, Malone RW, et al. Science. 1990;247(4949 Pt 1):1465-8. <\/a>Cited in 4,750 articles. Note that Robert was a student at Northwestern, and was never affiliated with University of Wisc.<a href=\"https:\/\/science.sciencemag.org\/content\/247\/4949\/1465\">https:\/\/science.sciencemag.org\/content\/247\/4949\/146<\/a>5<\/li>\r\n<li>\u00a0<\/li>\r\n<li>High levels of messenger RNA expression following cationic liposome mediated transfection tissue cultured cells. Malone R, Kumar R, Felgner P. NIH Conference: \u201cSelf-Cleaving RNA as an Anti-HIV Agent (abstract). Washington, DC June 198<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7682647\/\">9<\/a><\/li>\r\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7682647\/\">.<\/a><\/li>\r\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7682647\/\">Cationic liposome-mediated RNA transfection. Dwarki VJ, Malone RW, Verma IM. Methods Enzymol. 1993;217:644-<\/a>54. Cited in: 102 article<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7682647\/\">s. https:\/\/pubmed.ncbi.nlm.nih.gov\/7682<\/a>647\/<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Delivery of exogenous DNA (includes mRNA) sequences in a mammal P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Biotechnology Advances 1993: 15 (3-4), 763-763<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>For a deeper dive into the actual data, patent disclosures, meeting notes, lab books, etc, go to this webpage. <a href=\"https:\/\/rwmalonemdllc.com\/mrna-vaccine-docs\">https:\/\/rwmalonemdllc.com\/mrna-vaccine-docs<\/a><\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p><mark class=\"has-inline-color has-luminous-vivid-orange-color\" style=\"background-color: rgba(0,0,0,0); color: #ff6900;\"><strong>Patents and papers &#8211; from the 1990s<\/strong><\/mark><\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:list -->\r\n<ul>\r\n<li><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-6110898-A\">DNA vaccines for eliciting a mucosal immune response (includes mRNA)<\/a>. US Pat. Ser. No. 6,110,898. Inventors: RW Malone and Jill Glasspool Malone. Date of issue: 8\/29\/00. Cited in 40 articles. Priority Date: 1996.<\/li>\r\n<li>https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-6110898-A<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US5925623\">Formulations and methods for generating active cytofectin: polynucleotide transfection complexes. Robert W Malone, et al. US Pat. Ser. No. 5,925,623 7\/20\/99.<\/a><\/li>\r\n<li>https:\/\/patents.google.com\/patent\/US5925623<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/patents.justia.com\/patent\/5892071\">Cationic Transport Reagents. US Pat. Ser. No. 5,892,071 Robert W Malone, et. al. issued 4\/06\/99.<\/a><\/li>\r\n<li>https:\/\/patents.justia.com\/patent\/5892071<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US5824812\">Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin: polynucleotide transfection complexes.<\/a> Robert W Malone, et. al. US Pat. Ser. No. 5,824,812 issued 10\/20\/98.<\/li>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US5824812\">https:\/\/patents.google.com\/patent\/US5824812<\/a><\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US5744625A\/en\">Cationic Transport Reagents. Robert W Malone, et. al. US Pat. Ser. No. 5,744,625 issued 4\/28\/98.<\/a><\/li>\r\n<li>https:\/\/patents.google.com\/patent\/US5744625A\/en<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/patents.google.com\/patent\/US5527928A\/en\">Cationic Transport Reagents. <\/a><strong>Robert W Malone<\/strong>, et. al. US Pat. Ser. No. 5,527,928, date of issue: 6\/18\/96.<\/li>\r\n<li>https:\/\/patents.google.com\/patent\/US5527928A\/en<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/www.liebertpub.com\/doi\/abs\/10.1089\/10430349950017707?journalCode=hum\">Marked enhancement of macaque respiratory tissue transfection by aurintricarboxylic acid. Glasspool-Malone J<\/a>, \u2026, <strong>Malone RW<\/strong>. Gene Med. 2002;4(3):323-2.<\/li>\r\n<li>https:\/\/www.liebertpub.com\/doi\/abs\/10.1089\/10430349950017707?journalCode=hum<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11883098\/\">Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields<\/a>. Glasspool-Malone J,<strong> Malone RW.<\/strong> In <strong>Gene Therapy Method<\/strong>s: Methods Enzymol. 2002;346:72-91 https:\/\/pubmed.ncbi.nlm.nih.gov\/11883098\/<\/li>\r\n<li>\u00a0<\/li>\r\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11237682\/\">Cutaneous transfection and immune responses to intradermal nucleic acid vaccination<\/a> are significantly enhanced by in vivo electropermeabilization. Drabick JJ, Glasspool-Malone J, \u2026, Malone RW. Mol Ther. 2001;3(2):249-55. Cited in 192 articles.<\/li>\r\n<li>https:\/\/pubmed.ncbi.nlm.nih.gov\/11237682\/<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Theory and in vivo application of electroporative gene delivery. Somiari S, Glasspool-Malone J, \u2026 Malone RW. Mol Ther. 2000;2(3):178-87. Cited in 345 articles. https:\/\/pubmed.ncbi.nlm.nih.gov\/11237682\/<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Efficient nonviral cutaneous transfection. Glasspool-Malone J, \u2026, Malone RW. Mol Ther. 2000;2(2):140-6. Cited in 138 articles.<\/li>\r\n<li>https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1525001600901072<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. Berlyn KA, \u2026, Malone RW J Biotechnol. 1999;73(2-3):155-79<\/li>\r\n<li>https:\/\/pubmed.ncbi.nlm.nih.gov\/10486925\/<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Models of Cationic Liposome Mediated Transfection. Gene Therapy and Molecular Biology. Ahearn A, Malone RW. Vol 4. Gene Therapy and Molecular Biology 1999;4<\/li>\r\n<li>http:\/\/gtmb.org\/volumes\/Vol4\/_14FC%20MALONE%20159-170.pdf<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Cationic lipid-mediated gene delivery to murine lung: correlation of lipid hydration with in vivo transfection activity. Bennett MJ, \u2026, Malone RW, Nantz MH. J Med Chem. 1997;40(25):4069-78<\/li>\r\n<li>https:\/\/pubs.acs.org\/doi\/10.1021\/jm970155q<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Considerations for the design of improved cationic amphiphile-based transfection reagents. Bennett MJ, \u2026, Malone RW. Journal of Liposome Research 1996;6(3):545-65<\/li>\r\n<li>https:\/\/www.tandfonline.com\/doi\/abs\/10.3109\/08982109609031136<\/li>\r\n<li>\u00a0<\/li>\r\n<li>Structural and functional analysis of cationic transfection lipids: the hydrophobic domain. Balasubramaniam RP, \u2026, Malone RW. Gene Ther. 1996;3(2):163-72. cited in 172 articles.<\/li>\r\n<li>https:\/\/pubmed.ncbi.nlm.nih.gov\/8867864\/<\/li>\r\n<li>\u00a0<\/li>\r\n<li>A flexible approach to synthetic lipid ammonium salts for polynucleotide transfection. MJ Bennett, RW Malone, MH Nantz. Tetrahedron letters 36 (13), 2207-2210<\/li>\r\n<li>https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/004040399500276I<\/li>\r\n<\/ul>\r\n<!-- \/wp:list -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>For the written history of the early events, by Dr. Jill Glasspool Malone https:\/\/static1.squarespace.com\/static\/617d909092cd2314e37ebe67\/t\/617de3cd04bffe53342539cb\/1635640269719\/Jill%27s+letter+about+RNA+vaccination+generic+v5+June2021.pdf<\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>https:\/\/t.me\/RWMaloneMD\/1234<\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>&nbsp;<\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>&nbsp;<\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>Source: <a href=\"https:\/\/t.me\/RWMaloneMD\/1233\">https:\/\/t.me\/RWMaloneMD\/1233<\/a><\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>&nbsp;<\/p>\r\n<!-- \/wp:paragraph -->\r\n\r\n<!-- wp:paragraph -->\r\n<p>&nbsp;<\/p>\r\n<!-- \/wp:paragraph -->\r\n<p>,<\/p>\r\n<p><iframe id=\"SHR\" style=\"display: none; border: none;\" title=\"shr-utils\"><\/iframe><\/p> ","protected":false},"excerpt":{"rendered":"<p>Patentes del Dr. Malone de el.inventobdeblas vacunas que se usan en las vacunas Pfizer yvMODERN Early Patents priority dates from 1989The first patents: Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response (includes mRNA). P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Assigned to Vical, Inc [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":358,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[111],"tags":[116,115,34],"class_list":["post-311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech","tag-arnm","tag-robert-malone","tag-vacunas"],"_links":{"self":[{"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/posts\/311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/comments?post=311"}],"version-history":[{"count":5,"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/posts\/311\/revisions"}],"predecessor-version":[{"id":359,"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/posts\/311\/revisions\/359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/media\/358"}],"wp:attachment":[{"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/media?parent=311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/categories?post=311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mexusnews.com\/espanol\/wp-json\/wp\/v2\/tags?post=311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}